Does switching to a new antipsychotic improve outcomes?. Data from the CATIE Trial

Schizophrenia Research

Volumn 107, Issue 1, 2009, Pages 22-29

  Rosenheck, Robert A ^a   Davis, Sonia ^b   Covell, Nancy ^c   Essock, Susan ^c   Swartz, Marvin ^d   Stroup, Scott ^b   McEvoy, Joseph ^d   Lieberman, Jeffrey ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Columbia College of Physicians and Surgeons ^*  (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic medications; Quality of life; Schizophrenia

Indexed keywords

OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; HUMANS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 58149129309     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.09.031     Document Type: Article

References (34)

1. Addington D., Addington J., and Maticka-Tyndale E. A depression rating scale for schizophrenics. Schizophrenia Research 3 (1996) 247-251
2. Barnes T.R.E. A rating scale for drug induced akathisia. British journal of psychiatry 131 (1989) 222-223
3. Brown W.A., and Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another. Journal of Clinical Psychiatry 56 1 (1995) 30-34
4. Drake R.E., Osher F.C., Noordsy D.L., Hurlburt S.C., Teague G.B., and Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 16 10 (1990) 57-67
5. Essock S.M., Covell N.H., Davis S.M., Stroup S.S., Rosenheck R.A., and Lieberman J.A. Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 163 12 (2006) 2090-2095
6. First M.B., Spitzer R.L., Gibbon M.B., and Williams J.B. Structured Clinical Interview for Axes I and II DSM IV Disorders - Patient Edition (SCID-I/P) (1996), Biometrics Research Institute, New York State Psychiatric Institute, New York
7. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.M., Chrzanowski W., Martin S., and Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry 64 10 (2003) 1250-1257
8. Guy W. Abnormal involuntary movements. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharamcology (1976), National Institute of Mental Health, Rockville, MD (DHEW No. ADM 76-338)
9. Heinrichs D.W., Hanlon E.T., and Carpenter W.T. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10 (1984) 388-398
10. Huskamp H.A. Managing psychotropic drug costs: will formularies work. Health Affairs 22 5 (2003) 84-96
11. Institute of Medicine, Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century (2001), National Academy Press, Washington, D.C
12. Kane J.M., Meltzer H.Y., Carson W.H., McQuade R.D., Marcus R.N., Sanchez R., and for the Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 68 2 (2007) 213-223
13. Kay S.R., Fiszbein A., and Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 (1987) 261-276
14. Keefe R.S.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A., and for the CATIE Investigators and the Neurocognitive Working Group. Archives of general psychiatry 64 (2007) 633-647
15. Lamo I., de Naver A., Windhager E., Irmansyah F., Lindenbauer B., Rittmansberger G., Platz T., Jones A.M., and Altman C. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human Psychopharmacology: Clinical and Experimental 20 8 (2005) 573-581
16. Lehman A. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning. 11 (1988) 51-62
17. Lieberman J.A., Stroup S., McEvoy J., Swartz M., Rosenheck R., Perkins D., Keefe R.S.E., Davis S., Davis C.E., Hsiao J., Severe J., and Lebowitz B. for the CATIE investigators, 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. New England Journal of Medicine 353 12 (2005) 1209-1223
18. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S.E., Davis C.E., Severe J., Hsiao J.K., and for the CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163 (2006) 600-610
19. Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
20. Nurnberg H.G., Thompson P.M., and Hensley P.L. Antidepressant medication change in clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. Journal of Clinical Psychiatry 60 9 (1999) 574-579
21. Remington, G., Chue, P., Stip, E., Kopala, L., Girard, T. and Christensen, B., 2005. The crossover approach to switching antipsychotics: what is the evidence. Schizophrenia Research 76 (203) 267-272.
22. Rosenheck R.A., Leslie D., Sindelar J., Miller E.A., Lin H., Stroup S., McEvoy J., Davis S., Keefe R.S.E., Swartz M., Perkins D., Hsiao J., and Lieberman J.A. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163 12 (2006) 2080-2089
23. Ruhe H.G., Huyser S., Swinkels J.A.S., and Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in Major depressive disorder: a systematic review. Journal of Clinical Psychiatry 67 12 (2006) 1836-1855
24. Rush A.J. STAR*D What have we learned. American Journal of Psychiatry 164 2 (2007) 201-204
25. Salyers M.P., Bosworth H.B., Swanson J.W., Lamb-Pagone J., and Osher F.C. Reliability and validity of the SF-12 health survey among people with severe mental illness. Medical Care 38 11 (2000) 1141-1150
26. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiat Scand Suppl 212 (1970) 11-19
27. Simon G.E. Choosing a first-line antidepressant. Equal on average does not mean equal for everyone. JAMA 286 23 (2001) 3003-3004
28. Simon G.E., Psaty B.M., and Hrachovec J.B. Mora M. Principles for evidence-based drug formulary policy. Journal of General Internal Medicine 20 10 (2005) 964-968
29. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., and Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29 1 (2003) 15-31
30. Swartz, M.S., Wagner, H.R., Swanson, J.W., Stroup, T.S., McEvoy, J.P., Reimherr, F., Miller, D.D., McGee, M., Khan, A., Canive, J.M., Davis, S.M., Hsiao, J.K., Lieberman, J.A., 2008. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia Research 100 (1-3), 39-52.
31. Taylor D.M., Young C.L., Mace S., and Patel M. Early clinical experience with risperidone long-acting injection: a prospective, 6-mnth follow-up of 100 patients. Journal of Clinical Psychiatry 65 8 (2004) 1076-1083
32. Thase M.E., Blomgren S.L., Birkett M.A., Atewr J.T., and Tepner R.G. Fluoxetine treatment of patients who failed initial treatment with sertraline. Journal of Clinical Psychiatry 58 1 (1997) 16-21
33. Weiden P.J. Switching antipsychotics: an updated review with a focus on quetiapine. Journal of Psychopharmacology 20 1 (2006) 104-108
34. Zarate C.A., Kando J.C., Tohen M., Weiss M.K., and Cole J.O. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline. Journal of Clinical Psychiatry 57 2 (1996) 67-71